Andrew Bascand, Managing Director of Harbour Asset Management joins me to discuss new findings of the GLP-1 drug class, which has predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.

Listen in for your chance to get ahead of the markets.

LISTEN ABOVE

See omnystudio.com/listener for privacy information.